相关实验视频
Updated: Jul 17, 2025

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
具有抗癌和MET激酶向性质的新型quinazoline-1,2,3-triazole杂交物
Motahareh Mortazavi1, Masoomeh Eskandari1, Fatemeh Moosavi1
1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
针对MET激酶的新型quinazoline衍生物显示出强大的抗癌活性. 化合物8c和8h有效抑制癌细胞增殖,诱导细胞亡,并抑制球形模型中的瘤生长.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 像MET一样,受体氨酸激酶 (RTKs) 在癌症的发展中至关重要.
- 向瘤性RTK为癌症治疗提供了一个有希望的策略.
研究的目的:
- 设计,合成和评估具有1,2,3-triazole部分的新型quinazoline衍生物作为潜在的MET抑制剂和抗癌剂.
- 评估这些化合物的抗增殖,诱导亡和球体生长抑制作用.
主要方法:
- 基纳林衍生物的合成.
- 均的时间解析光 (HTRF) 测定和西部斑对于MET抑制.
- 对六种癌细胞系的抗增殖活性进行硫胺B测定.
- 酸酸酶试验用于球状体生长抑制.
- 附录五/化染色用于亡.
- 激酶面板选和分子对接.
主要成果:
- 化合物8c显示出显著的MET抑制能力.
- 化合物8c和8h表现出广泛的抗增殖作用,特别是对MET阳性细胞 (IC50低至6.1μM).
- 这些化合物抑制了球状细胞的生长,并在MET过度表达细胞中诱导了亡,PDGFRA被确定为额外的标.
结论:
- 含有1,2,3-triazole部分的奎纳林衍生物是有效的MET抑制剂.
- 化合物8c和8h由于其抗增殖和诱导亡的特性,具有作为向抗癌剂的潜力.
- 这些新型化合物需要进一步研究,以开发癌症治疗.
更多相关视频
05:17Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drugs that Destabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists